Education
About Us
Working with TipRanks
Follow Us
Climb Bio (CLYM)
NASDAQ:CLYM
Total Valuation
Climb Bio has a market cap or net worth of $87.17M. The enterprise value is ―.
Market Cap$87.17M
Enterprise Value―
Share Statistics
Climb Bio has 67,575,770 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding67,575,770
Owned by Insiders8.61%
Owned by Institutions60.94%
Financial Efficiency
Climb Bio’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -38.61%.
Return on Equity (ROE)-0.35
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-38.61%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-4.35M
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Climb Bio is -1.58. Climb Bio’s PEG ratio is ―.
PE Ratio-1.58
PS Ratio0.00
PB Ratio0.42
Price to Fair Value0.55
Price to FCF-5.90
Price to Operating Cash Flow-5.66
PEG Ratio―
Income Statement
In the last 12 months, Climb Bio had revenue of 0.00 and earned -73.90M in profits. Earnings per share was -1.14.
Revenue0.00
Gross Profit0.00
Operating Income-82.02M
Pretax Income-73.90M
Net Income-73.90M
EBITDA-30.36M
Earnings Per Share (EPS)-1.14
Cash Flow
In the last 12 months, operating cash flow was -15.56M and capital expenditures 0.00, giving a free cash flow of -15.56M billion.
Operating Cash Flow-15.56M
Free Cash Flow-15.56M
Free Cash Flow per Share-0.23
Dividends & Yields
Climb Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.66
52-Week Price Change-83.80%
50-Day Moving Average1.26
200-Day Moving Average3.29
Relative Strength Index (RSI)51.35
Average Volume (3m)153.82K
Important Dates
Climb Bio upcoming earnings date is Aug 19, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend Date―
Financial Position
Climb Bio as a current ratio of 31.41, with Debt / Equity ratio of 0.25%
Current Ratio31.41
Quick Ratio31.41
Debt to Market Cap0.00
Net Debt to EBITDA2.86
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Climb Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Climb Bio EV to EBITDA ratio is -0.98, with an EV/FCF ratio of -1.92.
EV to Sales0.00
EV to EBITDA-0.98
EV to Free Cash Flow-1.92
EV to Operating Cash Flow-1.92
Balance Sheet
Climb Bio has $150.92M in cash and marketable securities with $532.00K in debt, giving a net cash position of -$150.39M billion.
Cash & Marketable Securities$150.92M
Total Debt$532.00K
Net Cash-$150.39M
Net Cash Per Share-$2.23
Tangible Book Value Per Share$3.27
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Climb Bio is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside675.19% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast-61.95%